Henry Schein Reports Q3 2026 Results, Raises Full-Year EPS Guidance

What happened

Henry Schein reported third-quarter 2026 net sales of $3.47 billion and diluted GAAP earnings per share of $1.06, up 26.2% year over year. It raised its 2026 non-GAAP diluted EPS guidance to $5.50–$5.56.

Confirmed

Global impact / market context

Higher sales and profit show Henry Schein is selling more dental supplies and equipment, which means more profit per sale flows to the bottom line. The raised profit guidance signals management expects that strength to continue, a positive sign for investors holding HSIC stock.

Analyst inference

The results mix solid internal sales growth with one-time boosts from tariff refunds and prior-year accounting gains, so the underlying profit growth of 19.1% excluding those items is the cleaner read. The raised guidance suggests demand for dental and medical products remains steady.

Analyst inference

What to watch

1. Watch whether U.S. dental merchandise sales keep growing 8.6%, since volume gains and market-share gains drove that increase and support the raised profit outlook. Confirmed
2. Watch whether management's raised 2026 non-GAAP diluted EPS guidance of $5.50–$5.56 is met, since any shortfall would test investor confidence in the forecast. Proposed
3. Watch Global Value-Added Services sales, which fell 4.8%; a further decline could offset growth in dental merchandise and equipment and pressure overall revenue and profit. Analyst inference

Evidence

• Original source link unavailable